C
Cheng-Keng Chuang
Researcher at Memorial Hospital of South Bend
Publications - 142
Citations - 2404
Cheng-Keng Chuang is an academic researcher from Memorial Hospital of South Bend. The author has contributed to research in topics: Prostate cancer & Cancer. The author has an hindex of 22, co-authored 127 publications receiving 1967 citations. Previous affiliations of Cheng-Keng Chuang include Chang Gung University & Chang Gung Memorial Hospital.
Papers
More filters
Journal ArticleDOI
Genome-Wide Mutational Signatures of Aristolochic Acid and Its Application as a Screening Tool
Song Ling Poon,Song Ling Poon,See Tong Pang,John R. McPherson,Willie Yu,Willie Yu,Kie Kyon Huang,Peiyong Guan,Wen-Hui Weng,Ee Yan Siew,Ee Yan Siew,Yujing Liu,Hong Lee Heng,Hong Lee Heng,Soo Ching Chong,Soo Ching Chong,Anna Gan,Anna Gan,Su Ting Tay,Weng Khong Lim,Weng Khong Lim,Ioana Cutcutache,Dachuan Huang,Dachuan Huang,Lian Dee Ler,Lian Dee Ler,Maarja-Liisa Nairismagi,Maarja-Liisa Nairismagi,Ming Hui Lee,Ying Hsu Chang,Kai Jie Yu,Waraporn Chan-on,Waraporn Chan-on,Bin Kui Li,Yunfei Yuan,Chao Nan Qian,Kwai Fong Ng,Ching Fang Wu,Cheng Lung Hsu,Ralph M. Bunte,Michael R. Stratton,P. Andrew Futreal,Wing-Kin Sung,Wing-Kin Sung,Cheng-Keng Chuang,Choon Kiat Ong,Choon Kiat Ong,Steven G. Rozen,Steven G. Rozen,Patrick Tan,Bin Tean Teh,Bin Tean Teh +51 more
TL;DR: A “molecular signature” of AA-induced DNA damage is presented, which helps to explain the mutagenic effects of AA and may also be useful as a way to detect unsuspected AA exposure as a cause of cancer.
Journal ArticleDOI
Loss of tumor suppressor KDM6A amplifies PRC2-regulated transcriptional repression in bladder cancer and can be targeted through inhibition of EZH2.
Lian Dee Ler,Sujoy Ghosh,Xiaoran Chai,Aye Aye Thike,Hong Lee Heng,Ee Yan Siew,Sucharita Dey,Liang Kai Koh,Jing Quan Lim,Weng Khong Lim,Swe Swe Myint,Jia Liang Loh,Pauline Ong,Xin Xiu Sam,Dachuan Huang,Tony Kiat Hon Lim,Puay Hoon Tan,Sanjanaa Nagarajan,Christopher Cheng,Henry Ho,Lay Guat Ng,John Shyi Peng Yuen,Po-Hung Lin,Cheng-Keng Chuang,Ying-Hsu Chang,Wen-Hui Weng,Steven G. Rozen,Patrick Tan,Caretha L. Creasy,See-Tong Pang,Michael T. McCabe,Song Ling Poon,Bin Tean Teh +32 more
TL;DR: This study demonstrates that inactivating mutations of KDM6A, which are common in urothelial bladder carcinoma, are potentially targetable by inhibiting EZH2 and small-molecule inhibitors of EZh2 were effective against KDM 6A-null bladder cancer in multiple mouse models.
Journal ArticleDOI
Xanthogranulomatous pyelonephritis: experience in 36 cases.
Cheng-Keng Chuang,Ming-Kuen Lai,Phei-Lang Chang,Ming-hsiung Huang,Sheng-hsien Chu,Chi-ju Wu,Huei-Rong Wu +6 more
TL;DR: Xanthogranulomatous pyelonephritis occurred most frequently in middle-aged women with a history of recurrent urinary tract disorder and cephalothin plus gentamicin or tobramycin were the drugs of choice before surgical intervention.
Journal ArticleDOI
Magnetic-nanoparticle-modified paclitaxel for targeted therapy for prostate cancer
Mu-Yi Hua,Hung-Wei Yang,Cheng-Keng Chuang,Rung-Ywan Tsai,Wen-Jauh Chen,Kun-Lung Chuang,Ying-Hsu Chang,Heng-Chang Chuang,See-Tong Pang +8 more
TL;DR: Data indicate that this magnetically targeted drug delivery system provides more effective treatment of prostate cancer cells using lower therapeutic doses and thus with potentially fewer side-effects.
Journal ArticleDOI
Mutation signatures implicate aristolochic acid in bladder cancer development
Song Ling Poon,Mi Ni Huang,Yang Choo,John R. McPherson,Willie Yu,Hong Lee Heng,Anna Gan,Swe Swe Myint,Ee Yan Siew,Lian Dee Ler,Lay Guat Ng,Wen-Hui Weng,Cheng-Keng Chuang,John Sp Yuen,See-Tong Pang,Patrick Tan,Bin Tean Teh,Steven G. Rozen +17 more
TL;DR: This study demonstrates the utility of inferring mutagenic exposures from somatic mutation spectra and suggests that AA exposure is more extensive than previously thought both in terms of populations at risk and in types of cancers involved.